Gideon Capital Advisors’s DexCom DXCM Stock Holding History

Gideon Capital Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-9,708	Closed	-$347K	–	407
2018 Q3	$347K	Buy	+9,708	New	+$301K	0.16%	207

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Gideon Capital Advisors's DXCM Position: Q4 2018 in Review

Gideon Capital Advisors sold out of DexCom (DXCM) in Q4 2018, closing a stake of 9,708 shares — an estimated $347K sold.

Gideon Capital Advisors first reported a position in DXCM in Q3 2018 and held it in 1 quarter. The position peaked at $347K in Q3 2018. 415 funds tracked by Wall St. Rank hold DXCM as of Q4 2018.

Gideon Capital Advisors reported no remaining DexCom position as of Q4 2018 after selling out during the quarter.
Gideon Capital Advisors sold 9,708 DexCom shares in Q4 2018, an estimated $347K.
Gideon Capital Advisors first reported a position in DexCom in Q3 2018 and held it in 1 quarter.
Gideon Capital Advisors's DexCom position peaked at $347K in Q3 2018.
415 funds tracked by Wall St. Rank held DexCom as of Q4 2018.

Based on Gideon Capital Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.